Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05860959 · ClinicalTrials.gov registry record
SUBLOCADE Long-term Outcomes
A clinical trial, sponsored by Indivior.
- Completed
- Registry status
- 480
- Enrollment target
NCT05860959: Completed study, sponsored by Indivior.
NCT05860959 is a clinical trial that has completed, run by Indivior. The registered enrollment target is 480 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05860959 has completed, sponsored by Indivior.
- COMPLETED
- Registry status
- 480 participants
- Enrollment target
Study Summary
This study will provide the opportunity to generate data on the long-term use of SUBLOCADE under real-world conditions, and to observe enduring changes in lifestyle, health, and sociodemographic factors that are part of the recovery process. Long-term patterns of abstinence/opioid misuse as well as measures of participants' physical, psychological, social, and economic well-being will be monitored to better understand factors associated with recovery from opioid use disorder (OUD). Therefore, this study will observe participants up to a maximum of 4 years.
Primary Outcome
* Definition of early remission: None of the criteria for OUD has been met for at least 3 months but for less than 12 months with the exception that Criterion 4 ("Craving, or a strong desire or urge to use opioids,") may be met. * Definition of sustained remission: None of the criteria for OUD has been met for at least 12 months with the exception that Criterion 4 ("Craving, or a strong desire or urge to use opioids,") may be met.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 480 participants |
| Start Date | 2023-08-31 |
| Est. Completion | 2025-08-31 |
What the finished NCT05860959 record still lists
NCT05860959 is an observational study that tracks outcomes without assigning an intervention. The registered 480 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT05860959 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05860959 about?
NCT05860959 is a clinical study titled "SUBLOCADE Long-term Outcomes". This study will provide the opportunity to generate data on the long-term use of SUBLOCADE under real-world conditions, and to observe enduring changes in lifestyle, health, and sociodemographic factors that are part of the recovery process. Long-term patterns of abstinence/opioid misuse as well as ...
What is the current status of trial NCT05860959?
This trial is currently completed. The enrollment target is 480 participants. The study started on 2023-08-31. Estimated completion is 2025-08-31.
Who is sponsoring clinical trial NCT05860959?
This trial is sponsored by Indivior, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01954992 · 480 participants · Phase 3
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
- NCT03023696 · 480 participants · NA
Can Prophylactic Foraminotomy Prevent C5 Palsy
- NCT04948060 · 480 participants · NA
Tribally Engaged Approaches to Lung Screening (TEALS)
- NCT05053230 · 480 participants · NA
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI